A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients

Efficacy and Safety of Once-weekly Supaglutide Versus Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

This is a study to evaluate the efficacy and safety of Supaglutide injection in the treatment of type 2 diabetes patients with poor glycemic control after diet and exercise intervention.

This trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase III).

The primary outcome of the phase IIb period is to preliminarily evaluate the efficacy and safety of Supaglutide and to provide the recommended dosage for the Phase 3 period after 12-week treatment.

The primary outcome of the Phase III period is to evaluate the efficacy and safety of Supaglutide after 24-week, double-blind treatment. The secondary outcome is to evaluate the efficacy and safety of Supaglutide after 24-week, double-blinded plus 28-week, open-label treatment period.

Study Overview

• Status: Active, not recruiting
• Conditions: Type2 Diabetes
• Intervention / Treatment: Biological: Supaglutide injection; Other: placebo injection

Detailed Description

This trial includes a 2-week screening period, a 4-week induction period, a 24-week double-blind treatment period and a 28-week open-label treatment period, followed by a 4-week follow-up period and a follow-up visit.

sample size was calculated to be 552, including 140 subjects in the period of Phase IIb and 412 subjects in the period of Phase III.

Subjects were randomly assigned to once-weekly subcutaneously injected Supaglutide 1mg, 2mg, 3mg and placebo according to a 2:2:2:1 ratio. During the IIb period, after Interim analysis and IDMC(Independent Data Monitoring Committee) confirmed the RP3D ( Recommended phase 3 dosage ) high and low doses, subjects were randomly assigned to Supaglutide RP3D high dose, RP3D low dose and placebo group according to a 2:2:1 ratio.

• Study Type: Interventional
• Enrollment (Actual): 547
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210008
      • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female patients aged from 18 to 75;
2. Type 2 diabetes diagonsed at least 8 weeks and has not received any glucose-lowering medication within 8 weeks prior to screening;
3. During screening, HbA1c: 7.5% ≤ HbA1c ≤ 11%;
4. Before randomization : 7.5% ≤ HbA1c ≤ 10.5%;
5. During screening and before randomization: FPG< 13.9 mmol/L
6. 18.5 kg/m2 ≤ BMI ≤ 35 kg/m2;
7. without birth plan and voluntarily take effective contraceptive measures;
8. fully understood the study, voluntarily entered the study and signed the informed consent.

Exclusion Criteria:

1. Diabetes other than Type 2;
2. Any DPP-4 inhibitors and / or GLP-1 analogues were used within 3 months before screening;
3. Continuous use of insulin for more than 14 days in the previous year;
4. C-Peptide <0.3 nmol/L;
5. Diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar non ketonic diabetic coma occurred within 6 months before screening;
6. Unstable proliferative retinopathy or macular lesion, severe diabetic neuropathy, intermittent claudication or diabetic foot occurred within 6 months before screening;
7. Severe hypoglycemia occurred within 6 months before screening
8. Severe trauma infection or operation within one month before screening;
9. Blood donation or massive blood loss or transfusion within 3 months ;
10. Suspected active infection ;
11. Growth hormone therapy was performed within 6 months before screening;
12. Patients having received corticosteroid continuous ≥ 7 days through within 2 months ;
13. use any drugs or surgery with weight control effect within 2 months;
14. weight change of more than 5% within 3 months;
15. mean systolic pressure (SBP) ≥ 160mmhg and / or DBP ≥ 90 mmHg at screening, or new/changed antihypertensive drugs or adjusted dosage of antihypertensive drugs within 4 weeks before screening or before induction period
16. with a history of severe cardiovascular disease, high risk of stroke/stroke within 6 months before screening;
17. with a history of acute or chronic pancreatitis, symptomatic gallbladder , pancreatic injury and other risk factors for pancreatitis, or with blood amylase and/or blood lipase ≥1.5 times the upper limit of normal (ULN) at the time of screening or before randomization;
18. Calcitonin level ≥50 ng/L (pg/mL) during screening;
19. with a history of medullary thyroid cancer, multiple endocrine neoplasm (Men) 2A or 2B syndrome, or related family history;
20. with clinically significant abnormal gastric emptying , severe chronic gastrointestinal diseases , long-term use of drugs that have a direct impact on gastrointestinal peristalsis , or having undergone gastrointestinal surgery within 6 months before screening, are not suitable to participate in this clinical study according to the evaluation of the researchers;
21. suffering from hematological diseases or any disease causing hemolysis or erythrocyte instability ;
22. Uncontrolled hyperthyroidism or hypothyroidism;
23. with hemoglobinopathy that may affect the determination of HbA1c levels;
24. HBsAg, HCV-Ab, HIV-Ab, TPAb or COVID-19 nucleic acid tested positive;
25. serious mental illness;
26. drinking more than 14 standard units weekly within 6 months before screening ;
27. a history of organ transplantation or other acquired or congenital immune system diseases;
28. allergic to the active ingredients (GLP-1 and GLP-1 analogues) of the study drug;
29. clear contraindications for the use of metformin;
30. Any of the following conditions: the pacemaker was installed when screened; no pacemaker was installed, but 12 lead ECG showed degree II or III atrioventricular block, long QT syndrome or QTc interval ≥ 450ms (fridericia formula was used to calculate QTCF); Patients with New York Heart Function Classification III or IV; Or other abnormal cardiac function with clinical significance that is not suitable for clinical research judged by researchers;
31. acute or chronic hepatitis, or whose laboratory examination indexes meet one of the following criteria at the time of screening or before randomization : alanine aminotransferase (ALT) level ≥ 2.5 fold ULN, aspartate aminotransferase (AST) ≥ 2.5 fold ULN, fasting triglyceride (TG) > 5.7 mmol/L or 500 mg/dl; the glomerular filtration rate (EGFR) < 60 ml/min/1.73 m2 was calculated by CKD-EPI (epi - (SCR)) formula;
32. participated in clinical trials of other drugs or devices within 3 months before screening;
33. Medication compliance in the lead-in period was < 75% or > 125%;
34. Any other situation that researchers think may affect the patients' informed consent or compliance with the trial protocol, or the patients' participation in the trial may affect the trial results or their own safety.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Supaglutide RP3D high dose; during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made andRP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3 , subjets will be assigned to RP3D hign dose, RP3D low dose and placebo	Biological: Supaglutide injection; Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
Experimental: supaglutide RD3D Low dose; during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made and RP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3, subjets will be assigned to RP3D hign dose, RP3D low dose and placebo	Biological: Supaglutide injection; Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
Placebo Comparator: placebo; placebo injection	Other: placebo injection; placebo injection 0.5ml

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HbA1c	The change in mean HbA1c concentrations (%)from baseline with Supaglutide versus placebo	12 weeks for phase IIb; 24weeks and 52 weeks for phase III

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
FPG	Changes in FPG (mmol/L) relative to baseline	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
HbA1c<7.0% and <6.5%	The proportion of participants who achieved HbA1c target (HbA1c<7.0% and <6.5% Patient percentage)	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
Fasting insulin	Fasting insulin changes（pmol/L) relative to baseline	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
fasting C-peptide	Fasting C-peptide changes (nmol/L) relative to baseline	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
fasting glucagon	fasting glucagon changes (pg/ml) relative to baseline	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
Area under the curve of blood glucose	Area under the curve of blood glucose(AUC0-120min,mmol/L) during the MMTT	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
Area under the curve of insulin	Area under the curve of insulin (AUC0-120min,pmol/L) during the MMTT	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
Area under the curve of C-peptide	Area under the curve of C-peptide (AUC0-120min,nmol/L) during the MMTT	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
fasting lipid profiles	Changes in fasting lipid profiles relative to baseline(mmol/L)	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
weight	Weight change from baseline(kg)	12 weeks for phase IIb; 24weeks and 52 weeks for phase III
salvage treatment	Percentage of subjects receiving salvage treatment(%)	12 weeks for phase IIb; 24weeks and 52 weeks for phase III

Collaborators and Investigators

• Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
• Investigators: Principal Investigator: Dalong Zhu, M.D,Ph.D, Nanjing trum tower hospital affiliated to Nanjing university school of medizine

Study record dates

Study Major Dates

• Study Start (Actual): September 13, 2021
• Primary Completion (Anticipated): June 28, 2023
• Study Completion (Anticipated): July 23, 2023

Study Registration Dates

• First Submitted: July 28, 2021
• First Submitted That Met QC Criteria: August 5, 2021
• First Posted (Actual): August 6, 2021

Study Record Updates

• Last Update Posted (Actual): January 18, 2023
• Last Update Submitted That Met QC Criteria: January 16, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: YN011-301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No